CLINICAL TRIALS PROFILE FOR DOVONEX

505(b)(2) Clinical Trials for DOVONEX

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT02019355 ↗	Actinic Keratosis Study	Completed	Washington University School of Medicine	Early Phase 1	2013-10-01	The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition.
New Indication	NCT02019355 ↗	Actinic Keratosis Study	Completed	Washington University School of Medicine	Early Phase 1	2013-10-01	The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition.

All Clinical Trials for DOVONEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00243464 ↗	Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis	Completed	LEO Pharma	Phase 3	2005-09-01	The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol plus betamethasone dipropionate gel is more effective than twice daily treatment of calcipotriol scalp solution in patients with scalp psoriasis. The primary outcome is patients with clear or minimal disease after 8 weeks treatment. Further the occurrence of relapse and rebound after end of treatment in patients with clear or minimal disease will be investigated.
NCT00625326 ↗	Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis	Completed	Deltanoid Pharmaceuticals	Phase 2	2008-01-01	Low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia. Calcipotriol, the most thoroughly studied of the vitamin D analogs, was first approved in Europe in the early 1990s. It has been shown to be comparable or slightly more effective than class II corticosteroid ointments. However, patients had reduced levels of parathyroid hormone; mean serum and urine calcium were increased during treatment and hypercalciuria was observed. These effects were reversible with discontinuation of therapy. Thus, while calcipotriol ointment was shown to be effective, the potential for alterations in calcium homeostasis have limited its use to 100 g of ointment per week (0.5 mg calcipotriol/week). Work has continued on the creation of new vitamin D analogs, such as COL-121, with the intent of eliminating the adverse effects of hypercalcemia and hypercalciuria with a compound that is more stable and more easily administered.
NCT00764751 ↗	Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris	Completed	LEO Pharma	Phase 2	2008-09-01	This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis vulgaris. Subject will be treated for 4 weeks. All subjects will apply LEO 19123 cream to psoriasis lesions on the left or right side of the body and either Dovonex® cream or cream vehicle to lesions on the other side.
NCT00769184 ↗	Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis	Completed	NeoStrata Company, Inc.	N/A	2008-10-01	This is a 12 week bilateral study, consisting of 6 weeks of treatment and 6 weeks of follow-up. The purpose of the study is to compare the safety and effectiveness of combining and then following a high potency topical corticosteroid treatment with LCD treatment for moderate-to-severe localized plaque psoriasis.
NCT01012713 ↗	Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis	Completed	University of California, San Francisco	Phase 4	2010-06-01	This is a 12-week, open-label, pilot trial evaluating the efficacy and safety of the combination of Clobex® spray with excimer laser therapy as the initial treatment of generalized plaque psoriasis, followed by maintenance therapy with topical Vectical. The study will be conducted in three distinct periods, namely Period A, Period B, and Period C, each of 4 weeks duration. During Period A (weeks 1 through 4), patients will use Clobex® spray twice daily along with excimer laser treatments twice weekly with the Photomedex XTRAC® Velocity machine. The goal of Period A is to achieve Psoriasis Area Severity Index (PASI) 75 in 100% of patients within four weeks. During Period B (weeks 5 through 8), patients would be treated with topical Vectical® twice daily. Thus, there is a steroid-free interval during which patients will not be using Clobex® spray. The goal of Period B is to maintain the patient's response using only non-steroid options. During Period C of the study, patients will use Clobex® spray BID and Vectical® BID. Period C (weeks 9 through 12) will be a "booster" period in which the goal is to see if 100% of patients can achieve Psoriasis Area Severity Index (PASI) 90-100. Regarding excimer laser therapy: all patients will be receiving excimer laser therapy twice weekly for the first 6 weeks of the study (up to the halfway point) which is 12 excimer laser treatments. At that point, only those patients achieving

Clinical Trial Conditions for DOVONEX

Condition Name

Condition Name for DOVONEX
Intervention	Trials
Psoriasis	3
Actinic Keratosis	2
Plaque Psoriasis	1
Actinic Keratoses	1

Condition MeSH

Condition MeSH for DOVONEX
Intervention	Trials
Psoriasis	8
Keratosis, Actinic	3
Keratosis	2
Drug-Related Side Effects and Adverse Reactions	1

Clinical Trial Locations for DOVONEX

Trials by Country

Trials by Country for DOVONEX
Location	Trials
United States	44
Canada	2
France	1
Denmark	1
China	1

Trials by US State

Trials by US State for DOVONEX
Location	Trials
California	4
Missouri	3
Oregon	3
North Carolina	2
Illinois	2

Clinical Trial Progress for DOVONEX

Clinical Trial Phase

Clinical Trial Phase for DOVONEX
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for DOVONEX
Clinical Trial Phase	Trials
Completed	9
Not yet recruiting	2
Enrolling by invitation	1

Clinical Trial Sponsors for DOVONEX

Sponsor Name

Sponsor Name for DOVONEX
Sponsor	Trials
LEO Pharma	3
NeoStrata Company, Inc.	1
St Vincent's University Hospital, Ireland	1

Sponsor Type

Sponsor Type for DOVONEX
Sponsor	Trials
Other	7
Industry	7
NIH	2

Last updated: May 21, 2026

Dovonex (Calcipotriol) Clinical Trials Update, Market Analysis, and Exclusivity/Generic Outlook

Dovonex (calcipotriol) is a branded topical vitamin D analog used for plaque psoriasis. Public clinical-trial activity for the original product is limited in recent years, and the brand’s economics are driven primarily by mature generics and channel dynamics rather than near-term late-stage pipeline risk. The practical near-term “clinical trials update” for Dovonex is largely a shift from new efficacy trials to formulation, device, and formulation-label expansions within the topical dermatology space, while competitive pressure comes from widely available generic calcipotriol and combination products.

What is Dovonex (calcipotriol) and what is its current clinical-trials activity level?

Mechanism and formulation context

Calcipotriol is a vitamin D analog that regulates keratinocyte proliferation and differentiation and modulates immune signaling in psoriatic skin. Dovonex is marketed as a topical agent, historically in cream and ointment forms, with dosing regimes tied to body-surface-area and weekly maximum limits.

How to interpret “clinical trials update” for a mature topical

For long-marketed topical dermatology products like Dovonex, the observable “update” pattern is:

• Fewer large, pivotal phase 3 programs for the original active ingredient.
• More incremental regulatory or post-approval studies (bioequivalence, formulation, tolerability, use-pattern studies).
• Use of real-world evidence and comparative effectiveness studies in psoriasis care settings.

Because Dovonex is an established generic-vulnerable active ingredient, late-stage investment typically targets differentiated combinations (for example vitamin D analog plus corticosteroid or other anti-inflammatory dermatology classes) rather than repeating a calcipotriol pivotal trial.

What is the likely trial footprint in the public domain

A credible “clinical trials update” for Dovonex depends on identifiable, currently recruiting or newly completed interventional studies with the brand name or calcipotriol-specific formulations. Without a specific, verifiable trial list tied to Dovonex brand studies, the only defensible update is that Dovonex does not show the same kind of late-stage, brand-defining trial cadence as newer psoriasis biologics and small molecules.

Which companies compete with Dovonex and what is the market structure for topical calcipotriol in psoriasis?

Competitive set

Dovonex competes in plaque psoriasis against:

• Generic topical calcipotriol (cream/ointment).
• Fixed-dose or co-formulated combinations of vitamin D analogs with topical corticosteroids.
• Other topical actives such as topical calcineurin inhibitors, retinoids, keratolytics, and newer combination products in some jurisdictions.
• Systemic therapies that shift patient management toward biologics and oral small molecules for moderate-to-severe disease.

Market drivers that matter for Dovonex

• Prescribing behavior: clinicians often start with topical regimens for mild-to-moderate plaque psoriasis and reserve systemic therapies for higher severity.
• Formulary coverage: brand-to-generic pricing and plan incentives often determine whether Dovonex remains reimbursed or substituted.
• Adherence: topical tolerability and application burden affect persistence and demand.

Where Dovonex revenue is typically concentrated

For mature topical products, revenue concentrates in markets where:

• Branded product retains formulary positions due to historical contracts, pharmacist substitution rules, or patient preference.
• Generic intensity is lower (or where branded packaging remains favored).
• Combination products are present but do not fully displace standalone vitamin D analogs.

What market size and demand trends apply to calcipotriol/topical vitamin D analogs?

Demand trend

Topical vitamin D analogs are a durable psoriasis segment but face structural erosion as:

• Generic calcipotriol becomes the default.
• Combination products capture a higher share due to faster symptom control or simplified regimens.
• Moderate-to-severe patients shift to systemic biologics and oral agents, reducing the addressable topical population.

Elasticity indicators

Key demand sensitivities for Dovonex-like products:

• Pricing pressure from generic substitution.
• Payor reimbursement and step-therapy rules.
• Competitive intensity from combination products and newer topical standards of care.

What revenue projections are realistic for Dovonex over the next 3 to 5 years?

Base-case market math (brand vs generic reality)

For a mature topical brand with widely available generic calcipotriol, most forward-looking projections depend on one variable: how much of the market stays branded versus substituted. Without verified current unit share and net price, the only defensible projection structure is scenario-based.

Scenario framework for Dovonex

• Downside: accelerated generic substitution plus formulary churn to combination therapies. Brand share declines faster than total category growth.
• Base case: stable category volume but continued pricing compression. Brand share holds modestly via limited repricing or localized formulary strength.
• Upside: localized branded retention plus growth in topical management for mild-to-moderate patients, partially offset by combination shift.

Given typical topical brand trajectories, the base case is generally flat-to-declining revenues with continued margin compression rather than sustained growth.

What that means for investment and licensing

• For licensing partners, the limiting factor is usually branded IP value versus active ingredient generic status.
• For R&D teams, the opportunity is more often reformulation, new delivery systems, or combination rationales than defending stand-alone calcipotriol as a novel IP product.

What patents protect Dovonex (calcipotriol) and when do they expire?

What is the Orange Book status of Dovonex and what does that imply for generic entry risk?

These determinations require an Orange Book listing tied to the specific marketed dosage forms (for example, cream and ointment SKUs) and each listed patent’s expiration and regulatory exclusivity codes. Without a verifiable Orange Book entry set for the Dovonex specific application/strength/dosage form, it is not possible to accurately state patent numbers, expiration dates, or Orange Book exclusivity.

When does Dovonex lose exclusivity and what generic launch scenarios exist?

Loss-of-exclusivity and generic launch scenarios depend on:

• NDA-level patent expiry (if any remains listed).
• Patent term adjustments and court outcomes (if relevant).
• Any applicable regulatory exclusivity periods.
• Whether any Paragraph IV certifications have been filed for the same listed patents tied to the Dovonex product.

Without a documented listing or litigation docket tied to Dovonex, a timeline cannot be produced.

What patent litigation affects Dovonex and are there any Paragraph IV settlements?

Paragraph IV litigation status requires a specific set of cases (court, parties, docket, filings, settlement date, and product descriptions). Without those records tied to Dovonex, it is not possible to provide a factual litigation update.

How does Dovonex compare with other topical psoriasis treatments on effectiveness, safety, and regimen design?

Clinical differentiation

In plaque psoriasis, vitamin D analogs like calcipotriol provide:

• Reduced plaque scaling and thickness over time.
• Typical adverse effects of local irritation, dryness, and potential hypercalcemia risk at high use levels (generally managed via dosing limits).

Comparative performance versus alternatives varies by regimen and patient phenotype. Combination therapy often outperforms monotherapy in speed of improvement, while monotherapy can be favored for tolerability or long-term maintenance in some care pathways.

Where comparisons tend to land in practice

• Calcipotriol monotherapy is usually positioned for mild-to-moderate plaque psoriasis.
• Combination with topical corticosteroids can improve rapidity of clearance and support shorter treatment courses.
• For extensive disease or refractory cases, clinicians shift toward phototherapy and systemic therapies.

What formulations are protected for Dovonex (cream vs ointment vs solution), and what are typical IP barriers to reformulation?

Formulation patent coverage is product- and jurisdiction-specific and depends on:

• Composition-of-matter or formulation patents (vehicle, stabilizers, concentration ranges).
• Method-of-use patents (dosing regimens).
• Process patents (manufacturing method, scale-up, controls).

Without specific Dovonex formulation patent numbers and jurisdictions, it is not possible to list protected formulations or manufacturing/IP barriers.

What biosimilar or biologic risk exists for Dovonex?

Dovonex is a small-molecule topical vitamin D analog. Biosimilar frameworks and biosimilar exclusivity do not apply to calcipotriol. Competitive biologic risk is indirect through treatment migration from topical management to biologic systemic therapy in moderate-to-severe disease.

Key takeaways

• Dovonex is a mature topical calcipotriol product in plaque psoriasis with limited observable late-stage brand-defining clinical-trial activity.
• Market performance is primarily shaped by generic substitution and formulary dynamics rather than new efficacy generation.
• Forward revenue projection is scenario-dependent but structurally likely to show flat-to-declining revenues with continued margin pressure in most markets.
• Patent exclusivity, Orange Book status, generic entry risk, and litigation updates cannot be stated without a verified, product-specific patent listing and docket record.

FAQs

1. Is Dovonex still prescribed in the era of combination vitamin D analogs and topical steroids?
2. Do topical calcipotriol products face safety dosing limits that impact adherence and utilization?
3. How does psoriasis severity distribution (mild-to-moderate vs moderate-to-severe) affect the topical vitamin D analog category?
4. What substitution rules and formulary designs most influence whether Dovonex remains branded or switches to generics?
5. Are there meaningful clinical differences between cream and ointment calcipotriol formulations that change market share?

References

1. U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-21).
2. ClinicalTrials.gov. Search results for “calcipotriol” and “Dovonex” interventional studies. (Accessed 2026-05-21).